Tango Therapeutics

TNGXPre-clinical

Tango Therapeutics is a public biotechnology company developing next-generation targeted cancer therapies based on the principle of synthetic lethality. The company's discovery platform integrates CRISPR-based functional genomics and computational biology to identify novel drug targets in genetically defined patient populations. Tango's pipeline includes multiple programs targeting tumor suppressor gene loss, with its lead programs in clinical development. The company is strategically positioned to address significant unmet needs in precision oncology.

Market Cap

$1.7B

Employees

100-200

Focus

Biotech

TNGX · Stock Price

USD 11.93+1.70 (+16.62%)

Historical price data

AI Company Overview

Technology Platform

An integrated synthetic lethality discovery platform combining CRISPR-based functional genomics, computational biology, and translational research to identify and validate novel drug targets for genetically defined cancers.

Pipeline Snapshot

5 drugs in pipeline

Drug	Indication	Stage
TNG260 + Pembrolizumab	Non Small Cell Lung Cancer	Phase 1/2
TNG348 + Olaparib	Breast Cancer	Phase 1/2
S095035 + TNG462	MTAP-deleted Solid Tumors	Phase 1/2
TNG462 + Pembrolizumab	Locally Advanced Solid Tumor	Phase 1/2
TNG908	Locally Advanced Solid Tumor	Phase 1/2

Opportunities

Significant growth opportunities exist in expanding the clinical utility of its lead programs into additional genetically defined tumor types and combination regimens.

The synthetic lethality platform provides a sustainable engine for new pipeline candidates, offering long-term value creation.

Potential strategic partnerships for development or commercialization could accelerate and de-risk the path to market.

Risk Factors

Key risks include clinical trial failures, intense competition in targeted oncology, potential inability of the platform to consistently generate viable drug candidates, and dependence on future capital raises to fund operations through to commercialization.

The pre-revenue status makes the company sensitive to market sentiment and clinical data readouts.

Competitive Landscape

Tango faces competition from other biotechs and large pharma in synthetic lethality (e.g., Revolution Medicines, KSQ Therapeutics) and targeted oncology broadly. Its differentiation lies in its systematic discovery platform focused on tumor suppressor gene loss and its pipeline of first-in-class mechanisms like CoREST inhibition for immune evasion.

Publications

Patents

Pipeline